RecallRadar

FDA Drug recall D-0049-2021

Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-cou…

On 2020-10-28 the FDA classified a Class III recall of Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-cou… by Mylan Pharmaceuticals, citing out-of-specification organic impurity results obtained during routine stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0049-2021
ClassificationClass III
Statusterminated
Initiated2020-10-02
Published2020-10-28
Last updated2026-09-13 11:52 UTC
CompanyMylan Pharmaceuticals
DistributionUS

Product

Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-count bottles (NDC 0378-3002-05), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Reason

Out-of-specification organic impurity results obtained during routine stability testing.

Identifiers

ndc0378-3001-77
ndc0378-3002-77
ndc0378-3003-77
ndc0378-3002-05
code_infoLot #: a) 8095666, Exp. Date July 2021 b) 3104664, Exp. Date July 2021

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0049-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.